Evidence item

The primary study reports 100% bioactivity after over two months at 37°C and non-inferior immune responses in rodents and nonhuman primates. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15622

Source: Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI · locator {} · excerpt hash sha256:380812fb3b993698ea1ff7b8c1b8e2167947f5aafe8e741de49457fcbff86bf8

Exact excerpt

We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months. In rodents and non-human primates, thermostable, solid-state vaccine formulations induced antigen-specific immune responses non-inferior to those elicited by intramuscular delivery of freshly prepared soluble vaccines.

Linked claims

Claim	Direction	Relevance	Steps	Counted
0171cfbc	SUPPORT	DIRECT	0	yes

Audits

None.